Monoclonal antibodies: Pharmacokinetics as a basis for new dosage regimens?

The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL

(2012) C. Muller et al.   BLOOD

A Guide to Rational Dosing of Monoclonal Antibodies

(2012) Shuang Bai et al.   CLINICAL PHARMACOKINETICS

1BA Subcutaneous Administration of Trastuzumab in Patients with HER2-positive Early Breast Cancer: Results From the Phase III Randomised, Open-label, Multi-centre Neoadjuvant-adjuvant HannaH Study

(2012) C. Jackisch et al.   EUROPEAN JOURNAL OF CANCER

Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response

(2012) U. Jager et al.   HAEMATOLOGICA

Pharmacokinetic Models for FcRn-Mediated IgG Disposition

(2012) Jim J. Xiao   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Population Pharmacokinetics of Rituximab in Patients With Chronic Lymphocytic Leukemia

(2012) Jing Li et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

(2012) Gustavo Ismael et al.   LANCET ONCOLOGY

Rituximab resistance

(2011) Andrew R. Rezvani et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Interindividual Variability of Response to Rituximab: From Biological Origins to Individualized Therapies

(2011) G. Cartron et al.   CLINICAL CANCER RESEARCH

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

(2010) Ron J. Keizer et al.   CLINICAL PHARMACOKINETICS

Trastuzumab

(2010) Karly P. Garnock-Jones et al.   DRUGS

Clinical Ramifications of the MHC Family Fc Receptor FcRn

(2010) Derry C. Roopenian et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Trastuzumab Pharmacokinetics Influenced by Extent Human Epidermal Growth Factor Receptor 2–Positive Tumor Load

(2010) Thijs H. Oude Munnink et al.   JOURNAL OF CLINICAL ONCOLOGY

Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR

(2010) Takuo Suzuki et al.   JOURNAL OF IMMUNOLOGY

Rituximab: Mechanism of Action

(2010) George J. Weiner   SEMINARS IN HEMATOLOGY

Hyaluronidase: a review of approved formulations, indications and off-label use in chronic pain management

(2009) Amber L Dunn et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma

(2009) Hélène Blasco et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

Intensive Loading Dose of Trastuzumab Achieves Higher-Than-Steady–State Serum Concentrations and Is Well Tolerated

(2009) Brian Leyland-Jones et al.   JOURNAL OF CLINICAL ONCOLOGY

A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs

(2007) Jasmine P. Davda et al.   INTERNATIONAL IMMUNOPHARMACOLOGY